Grail, a US spinout from Illumina (NSDQ: ILMN) that is developing blood-based cancer detection tests, is considering a $500 million Hong Kong IPO (see story). Last year, Grail completed a $900 million Series B fundraising, the largest ever. In June, Grail …
( read original story …)